THE PRESENT INVENTION PROVIDES DENGUE VIRUS VACCINES AND IMMUNOGENIC COMPOSITIONS FOR ADMINISTRATION TO HUMAN SUBJECTS. THE VACCINE COMPOSITIONS OF THE PRESENT INVENTION COMPRISE RECOMBINANTLY PRODUCED MONOMERIC AND/OR DIMERIC FORMS OF TRUNCATED DENGUE VIRUS ENVELOPE GLYCOPROTEIN THAT, WHEN FORMULATED TOGETHER WITH AN ADJUVANT AND A PHARMACEUTICALLY ACCEPTABLE CARRIER, INDUCE BALANCED TETRAVALENT IMMUNE RESPONSES. IN PREFERRED EMBODIMENTS OF THE COMPOSITIONS DESCRIBED HEREIN, THE DEN4 PROTEIN COMPONENT IS A DIMERIC FORM OF DEN4. THE COMPOSITIONS ARE DESIGNED TO BE ACCEPTABLE FOR USE IN THE GENERAL POPULATION, INCLUDING IMMUNOSUPPRESSED, IMMUNOCOMPROMISED, AND IMMUNOSENESCENT INDIVIDUALS. ALSO PROVIDED HEREIN ARE METHODS OF INDUCING A PROTECTIVE IMMUNE RESPONSE IN A HUMAN PATIENT POPULATION BY ADMINISTERING THE COMPOSITIONS DESCRIBED HEREIN TO THE PATIENTS. (NO SUITABLE FIGURE)